Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q1 2024 · 10-Q
Revenue$4.76M$4.76M+27.2% vs Q1 2023 Net Income-$775.00K-$775.00KN/M vs Q1 2023 EPS, diluted—
Gross Profit$2,246,000+24.1% Operating Income-$763,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flow$481,000N/M Margins · derivedGross margin47.2%−1.2 pt vs Q1 2023
Operating margin-16.0%−3.3 pt vs Q1 2023
Net margin-16.3%−3.1 pt vs Q1 2023
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end